Therapy Directory

Fulvestrant clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention. Browse Fulvestrant recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

294

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Breast Cancer
Interventions: Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 30
States / cities: Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 26 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Breast Cancer
Interventions: Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 26
States / cities: Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Bortezomib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 21
States / cities: Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more

Conditions: Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Interventions: SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Copanlisib, Fulvestrant; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Sacramento, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions: NERATINIB, FULVESTRANT; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions: NUV-422, Fulvestrant; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more

Conditions: Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
Interventions: Abemaciclib, Fulvestrant; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Orange, California

Conditions: Invasive Breast Cancer
Interventions: Fulvestrant, Anastrazole; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Breast Cancer, Prostate Cancer, Advanced Solid Tumors
Interventions: AZD5363, Enzalutamide, Fulvestrant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Middletown, New Jersey • Harrison, New York • New York, New York

Conditions: Cancer, Solid Tumors
Interventions: Vevorisertib, Fulvestrant, Paclitaxel; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more

About this Fulvestrant clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fulvestrant.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fulvestrant clinical trials

Filter and sort this therapy

Live official records

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Fulvestrant + Neratinib In Breast Cancer

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

About this Fulvestrant clinical trials directory page